Showing results (451-460 of 523) with videos related to
Sort By:
Pageof 53
Molecular Cancer|June 29, 2026
A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunctionFilippo Gustavo Dall'Olio, Wael Salem Zrafi, Xinran Song, et al.Clinical Lung Cancer|October 18, 2024
Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM)Diego Enrico, Juan Elias Gomez, Danilo Aguirre, et al.Oncoimmunology|May 4, 2016
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLCBenjamin Besse, Mélinda Charrier, Valérie Lapierre, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 18, 2020
High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni SyndromeLaura Mezquita, Maria Jové, Ernest Nadal, et al.Therapeutic Advances in Medical Oncology|June 30, 2025
Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)Miguel García-Pardo, Marta García de Herreros, Edouard Auclin, et al.European Journal of Cancer (Oxford, England : 1990)|August 23, 2021
Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control studyCharlotte Cabanié, Samy Ammari, Sophie Hans, et al.Lung Cancer (Amsterdam, Netherlands)|February 22, 2023
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancerEdouard Auclin, Jose Benitez-Montanez, Marco Tagliamento, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2026
Intratumoral Immune Heterogeneity Drives Divergent Outcomes to PD-(L)1 Blockade in Lung CancerLaura Cipriani, Davide Mascolo, Stefano Scalera, et al.Nature Cancer|February 5, 2022
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohortLaurence Albiges, Stéphanie Foulon, Arnaud Bayle, et al.Nature Communications|October 4, 2024
The genomic and transcriptomic landscape of metastastic urothelial cancerYohann Loriot, Maud Kamal, Laurene Syx, et al.Pageof 53